Clinical trial NCT00053794 (phase 2, status: completed)
Conditions: endometrial cancer, sarcoma
ICD codes: N85.00, N85.01, N85.02, N99.85, C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, C92.32
Drugs: perifosine
SMILES: CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed metastatic or locally advanced soft tissue sarcoma that is
             incurable by standard therapies, including any of the following types:

               -  Uterine sarcomas

                    -  Mixed mesodermal

                    -  Leiomyosarcoma

                    -  Endometrial stromal sarcoma

               -  Alveolar soft part sarcoma

               -  Angiosarcoma/lymphangiosarcoma

               -  Fibrosarcoma

               -  Hemangiopericytoma

               -  Leiomyosarcoma

               -  Liposarcoma

               -  Malignant fibrous histiocytoma

               -  Neurogenic sarcoma

               -  Pleomorphic rhabdomyosarcoma

               -  Synovial sarcoma

               -  Unclassifiable sarcoma

               -  Undifferentiated sarcoma

          -  Excluded diseases include the following:

               -  Bone sarcomas (e.g., osteosarcoma, Ewing's sarcoma, chondrosarcoma)

               -  Embryonal rhabdomyosarcoma

               -  Carcinosarcoma

               -  Kaposi's sarcoma

               -  Malignant mesothelioma

               -  Neuroblastoma

               -  Gastrointestinal stromal tumor

          -  At least 1 unidimensionally measurable site of disease (outside the previously
             irradiated area) defined as:

               -  At least 20 mm by x-ray or physical exam

               -  At least 10 mm by spiral CT scan

               -  At least 20 mm by non-spiral CT scan NOTE: Bone lesions are not considered
                  measurable

        NOTE: Patients whose sole site of disease is within a previously irradiated area are
        allowed if there is evidence of progression or new lesions in the irradiated field

          -  No known brain metastases

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  At least 12 weeks

        Hematopoietic

          -  Absolute granulocyte count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic

          -  Bilirubin no greater than upper limit of normal (ULN)

          -  AST no greater than 2.5 times ULN

        Renal

          -  Creatinine no greater than ULN

        Cardiovascular

          -  No symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No prior allergic reactions attributed to compounds of similar chemical or biological
             composition to perifosine

          -  No other malignancy within the past 5 years except adequately treated nonmelanoma skin
             cancer or curatively treated carcinoma in situ of the cervix

          -  No active or ongoing infection

          -  No psychiatric illness or social situation that would limit compliance with study
             requirements

          -  No other concurrent uncontrolled illness

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior systemic chemotherapy for metastatic or locally advanced disease

          -  At least 6 months since prior adjuvant chemotherapy

          -  No other concurrent cytotoxic chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  See Disease Characteristics

          -  At least 4 weeks since prior radiotherapy (except low-dose, non-myelosuppressive
             radiotherapy)

          -  No concurrent radiotherapy to the sole site of measurable disease or for progressively
             symptomatic disease

        Surgery

          -  At least 4 weeks since prior major surgery

        Other

          -  No other concurrent anticancer therapy or investigational agents